

## Special Issue

# Angiogenesis and Inflammation in Biological Barriers 2.0

### Message from the Guest Editor

Owing to the success of our first issue on angiogenesis and inflammation in biological barriers, I am pleased to announce the launch of a second volume. This Special Issue will gather publications that focus on two key processes, angiogenesis and inflammation, which strongly contribute to the functioning of highly vascularized biological barriers (BB). The scope of Volume 2 will be more focused on BB-associated pathologies. Biological barriers are essential for the integrity and proper function of many vertebrate organs and are critical for the regulation of tissue homeostasis and protection against pathogens or other tissue-damaging agents. Recent studies have uncovered the role of new inflammatory and angiogenic proteins in the control of the integrity of these BB as well as their physiological functioning. Deregulations in the expression and/or function of these proteins may explain BB-associated pathologies, such as infections, exacerbated inflammation, tissue injury, and cancer. This Special Issue welcomes original articles and reviews focused on pathological angiogenesis and inflammation in highly vascularized biological barriers.

---

### Guest Editor

Dr. Nadia Alfaidy

Biology and Biotechnology for Health, Biosanté, INSERM U1292, Grenoble, France

---

### Deadline for manuscript submissions

closed (15 August 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/84149](https://mdpi.com/si/84149)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).